Sort by: after hours % change | delayed % change | gain open | gain high | gain close | publishing date
tags : Research symbols : PIRS save search
Pieris Pharmaceuticals Announces Milestone Achievement for Boston Pharmaceuticals' Initiation of Phase 1/2 Study of BOS-342, a 4-1BB/GPC3 Immuno-Oncology Bispecific
Published: 2023-08-17 (Crawled : 13:00) - biospace.com/
PIRS | $0.1455 -6.25% -6.67% 1.9M
|
Health Technology
|
| O: 5.11%
H: 10.24%
C: 2.81%
bos-342 pharmaceuticals milestone study
Pieris Pharmaceuticals Announces $5 Million Milestone from Seagen for Initiation of Phase 1 Trial of CD228 x 4-1BB Bispecific Molecule (Mabcalin SGN-BB228 (PRS-346)
Published: 2023-01-10 (Crawled : 14:00) - biospace.com/
PIRS | $0.1455 -6.25% -6.67% 1.9M
|
Health Technology
|
| O: 4.69%
H: 5.97%
C: 5.22%
cd228 pharmaceuticals trial milestone
Pieris Pharmaceuticals Announces PRS-220 Presentation at ERS Highlighting Preclinical Data for CTGF Inhibitor
Published: 2021-08-24 (Crawled : 15:00) - biospace.com/
PIRS | $0.1455 -6.25% -6.67% 1.9M
|
Health Technology
|
| O: 0.46%
H: 0.0%
C: -4.38%
presentation preclinical pre-clinical
Pieris Pharmaceuticals Receives Orphan Drug Designation for Cinrebafusp Alfa for the Treatment of Gastric Cancer
Published: 2021-06-24 (Crawled : 12:15) - biospace.com/
PIRS | $0.1455 -6.25% -6.67% 1.9M
|
Health Technology
|
| O: 5.65%
H: 22.19%
C: 16.84%
treatment cancer drug designation
Gainers vs Losers
| 67% | 33% |
Top 10 Gainers
AGBA | News | $1.26 215.0% 68.25% 130M
|
Finance
EGOX | $0.0515 43.06% 30.1% 330M
|
OLB 4 | $0.33 -14.95% 25.53% 840K
|
Technology Services
NVFY | $2.77 31.28% 23.83% 33M
|
Consumer Durables
ZCMD | $1.87 28.97% 22.46% 31M
|
Commercial Services
RCON | $0.1112 13.01% 21.28% 1.7M
|
Distribution Services
INSG | $3.03 25.21% 20.13% 330K
|
Electronic Technology
GCTK | $0.8191 22.25% 18.2% 190K
|
Manufacturing
WLGS | $0.59 18.0% 17.9% 2.3M
|
ASNS | $0.828 21.75% 17.86% 18K
|
Your saved searches
Save your searches and get alerts when important news are released.